Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain KITE message board posts where the ticker symbol KITE has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest KITE SEC Filings

Filings Format Description Filing Date File/Film Number
15-12B  Documents Securities registration termination [Section 12(b)]
Acc-no: 0001193125-17-309956 (34 Act)  Size: 9 KB
2017-10-13 001-36508
171137049
UPLOAD  Documents [Cover]SEC-generated letter
Acc-no: 0000000000-17-036237 Size: 35 KB
2017-10-12
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-056240 Size: 19 KB
2017-10-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-056239 Size: 13 KB
2017-10-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-056237 Size: 24 KB
2017-10-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-056236 Size: 22 KB
2017-10-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-056235 Size: 15 KB
2017-10-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-056234 Size: 19 KB
2017-10-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-056233 Size: 18 KB
2017-10-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-056232 Size: 20 KB
2017-10-05
More KITE SEC Filings


Related news from
Fri, 08 Dec 2017
15:48:00 +0000
Gilead Sciences: Look Who's Shopping!
Shares of Gilead Sciences (GILD) are higher Friday, after it announced its acquisition of Cell Design Labs. Kite Pharma, which Gilead bought earlier this year, already owned some 12% of the firm, so Gilead ...
Fri, 08 Dec 2017
14:43:02 +0000
Gilead Sciences to Acquire Cell Design Labs for $567 Million
Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.
Fri, 01 Dec 2017
10:05:00 +0000
Gene Therapy Is Booming, But How Will We Manage The Costs?
Three leading executives in the booming field of gene therapy debated the question of whether the pricey therapies should be reimbursed based on whether or not they cure patients.
Thu, 30 Nov 2017
22:16:36 +0000
Does Gilead's Kite Acquisition Offer A New Buying Opportunity?
Gilead caught an upgrade following its Kite buyout and the promise shown with new cancer drugs.
Thu, 30 Nov 2017
18:58:47 +0000
Maxim Explains Why Gilead Sciences Is A Now A Buy
Gilead Sciences, Inc. (NASDAQ: GILD ) stands to benefit on multiple fronts, which prompted an analyst to upgrade the shares of the company Thursday. The Analyst Maxim Group analyst Jason McCarthy upgraded ...
Thu, 30 Nov 2017
18:13:29 +0000
Gilead Sciences Stock Upgraded: This Is the Power of Free
Wall Street cannot resist buying a stock on sale -- and for better or worse, Gilead often seems to be on sale.
Tue, 14 Nov 2017
20:03:41 +0000
7 Life Science Stocks to Buy Today
Biotech and life sciences stocks have had a great run-up so far in 2017. Through the end of October, the S&P Biotechnology Select Sector Industry Index (SPSIBI) is up 52%. That makes the life science stocks some of best performers around. And what’s not to like?
Wed, 08 Nov 2017
18:14:00 +0000
6 Reasons Gilead Didn't Overpay for Kite
Shares of Gilead Sciences (GILD) have been on a steady downward slide since it hit a 52-week high in early September. Add to that, some investors remain unconvinced that Gilead didn’t overpay when it bought Kite Pharma for $12 billion. What do investors think of this deal and where are we?
Thu, 02 Nov 2017
05:00:11 +0000
Juno touts latest cancer drug results after rivals win FDA approval
Juno Therapeutics Inc. has announced new cancer trial results that could help the drugmaker leapfrog key competitors in the rapidly emerging cancer immunotherapy industry. Juno said the latest data from its lead product candidate, called JCAR017, are stronger than from Novartis Pharmaceuticals Corp. and Kite Pharma Inc. Both rivals recently won Food and Drug Administration approval to start selling their CAR-T (chimeric antigen receptor T cell) treatments. "There's been this odd belief that all CAR-Ts are the same," Juno President of Research and Development Dr. Sunil Agarwal said Wednesday.
Tue, 24 Oct 2017
19:24:00 +0000
3 Healthcare Value Stocks
It might be hard to find value-priced healthcare stocks, but Gilead Sciences, Masimo, and AbbVie qualify if investors know how to look at them.
Thu, 19 Oct 2017
17:03:40 +0000
Gilead shares up after FDA approves breakthrough cancer treatment
The FDA has approved a new cancer treatment developed by Gilead's $11B acquisition Kite Pharma. Yahoo Finance’s Alexis Christoforous, Rick Newman, and Nicole Sinclair have more.
Thu, 19 Oct 2017
14:22:00 +0000
Gilead: Congratulations…But You Still Overpaid for Kite
Less than two months ago, Gilead Sciences (GILD) announced an almost $12 billion deal to buy Kite Pharma. Late yesterday, the FDA approved Kite’s CAR-T cancer therapy for adults with advanced lymphoma. It uses genetically-engineered T-cells to attack cancer cells, and it is only the second such therapy to make it through the FDA.
Thu, 19 Oct 2017
04:02:04 +0000
Gilead Gets FDA Approval for New Cancer Therapy
Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.
Tue, 17 Oct 2017
12:39:06 +0000
Gilead Sciences on the Street: Analyst Recommendations in October
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy."
Mon, 16 Oct 2017
12:01:09 +0000
6 Top Biotech Companies In Innovation Earn Recognition In New Awards
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
Mon, 16 Oct 2017
11:45:07 +0000
Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field
Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.
Fri, 13 Oct 2017
15:33:05 +0000
It’s Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock
Then there was the demise of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), followed by an EpiPen scandal at Mylan N.V. (NASDAQ:MYL). While GILD stock also fell, the reasons were largely unrelated to the scandals which plagued its peers. The company’s big Hepatitis C Virus (HCV) drug worked really well.
Tue, 10 Oct 2017
14:57:03 +0000
Going Long Pfizer Inc. (PFE) Stock Is an Easy Pill to Swallow
Pfizer Inc. (NYSE:PFE) has had a decent year, rising 11% year-to-date and 8% in the past 12 months. Fundamentally, PFE stock could play catch up since its value is mid-range compared to its competitors. Today’s trade is bullish PFE stock.
Sat, 07 Oct 2017
17:00:00 +0000
Here's Why Juno Therapeutics Stock May Still Be Worth Buying
Juno Therapeutics stock has been on the move as investors speculate on the next CAR-T buyout target. But there are other compelling reasons to own this stock right now.
Tue, 03 Oct 2017
22:14:10 +0000
The 5 Best M&A Deals of 2017 (So Far!)
Over the past few years, consolidation has become an important trend in nearly every major global industry. To celebrate this, we've compiled our list of the most important M&As of 2017!



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "I absolutely LOVE ValueForum, and consider this site the most important tool I have for investing and/or trading because of the incredible information at just one site. I have learned so much from reading messages posted here that I recommend to the new comer to select an area of investing that is of interest and then read those posts starting with most current. I am sure you will gain information and learn techniques that can be applied to other areas/sectors of investing. This is an 'Invaluable' forum." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards